Lv13
50 积分 2022-07-20 加入
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
1天前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
1天前
已完结
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
2年前
已完结
皖公网安备34019202002308
